Moore Capital Management, LP Genmab A/S Transaction History
Moore Capital Management, LP
- $4.06 Billion
- Q1 2025
A detailed history of Moore Capital Management, LP transactions in Genmab A/S stock. As of the latest transaction made, Moore Capital Management, LP holds 35,400 shares of GMAB stock, worth $725,700. This represents 0.03% of its overall portfolio holdings.
Number of Shares
35,400Holding current value
$725,700% of portfolio
0.03%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding GMAB
# of Institutions
248Shares Held
66.2MCall Options Held
729KPut Options Held
398K-
Alliancebernstein L.P. New York, NY14.7MShares$302 Million0.11% of portfolio
-
Orbis Allan Gray LTD Hamilton, D05.71MShares$117 Million0.8% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$104 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.43MShares$90.7 Million0.02% of portfolio
-
Harding Loevner LP Bridgewater, NJ2.88MShares$59.1 Million0.45% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $13.5B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...